Fevipiprant

Unassigned

New Medicines

Nasal polyposis with chronic rhinosinusitis (CRSwNP) and concomitant asthma

Information

New molecular entity
Novartis
Novartis

Development and Regulatory status

Discontinued
Discontinued
Discontinued
Feb 20 · Development of fevipiprant discontinued as PIII LUSTER studies (in patients with asthma) failed to met primary outcome [3].

Category

A CRTh2 antagonist; also termed DP2 antagonist, targets prostaglandin D2 receptors
Nasal polyps are lesions arising from the nasal mucosa, occurring at any site in the nasal cavity or paranasal sinuses but most frequently seen in the clefts of the middle meatus. Nasal polyps can be considered as part of the spectrum of chronic rhinosinusitis. The population prevalence is reported as around 4%, with no racial predilection. The male-to-female ratio is approximately 2:1 [1].
Nasal polyposis with chronic rhinosinusitis (CRSwNP) and concomitant asthma
Oral

Allergic and/or severe asthma, added to GINA steps 4 and 5 standard-of-care (SoC) asthma therapy

Information

New molecular entity
Novartis
Novartis

Development and Regulatory status

Discontinued
Discontinued
Discontinued
Dec 19 · Novartis announce it is stopping development of fevipiprant after it failed to reduce exacerbation rates in two studies in patients with moderate to severe disease [10].

Category

A CRTh2 antagonist
There were over 79,800 emergency hospital admissions for asthma in the UK in 2008/09. Of these, 30,740 were children aged 14 years or under. There were 1,131 deaths from asthma in the UK in 2009 (12 were children aged 14 years or under). An estimated 75% of admissions for asthma are avoidable and as many as 90% of the deaths from asthma are thought to be preventable.
Allergic and/or severe asthma, added to GINA steps 4 and 5 standard-of-care (SoC) asthma therapy
Oral

Evidence based evaluations